LB Pharmaceuticals Inc SEC filings LBRX
LB Pharmaceuticals Inc has 143 filings in SEC EDGAR's recent list, going back to Dec 15, 2016. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| EFFECT | Filing | Oct 5, 2026 | — |
| POS AM | Filing | Oct 1, 2026 | — |
| S-3ASR | Automatic shelf registration | Oct 1, 2026 | — |
| 424B3 | Prospectus | Sep 15, 2026 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
| 424B3 | Prospectus | Sep 3, 2026 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 3, 2026 | Sep 3, 2026 |
| 424B3 | Prospectus | Aug 11, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 424B3 | Prospectus | Jul 29, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 29, 2026 | Jul 28, 2026 |
| 424B3 | Prospectus | Jul 22, 2026 | — |
| 8-K |
Current report
Other events
|
Jul 22, 2026 | Jul 22, 2026 |
| 424B3 | Prospectus | Jun 10, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Jun 10, 2026 | Jun 8, 2026 |
| 424B3 | Prospectus | Jun 9, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2026 | Jun 3, 2026 |
| 424B3 | Prospectus | May 12, 2026 | — |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 3, 2026 |
| EFFECT | Filing | Apr 14, 2026 | — |
| 424B3 | Prospectus | Apr 14, 2026 | — |
| CORRESP | Letter to the SEC | Apr 10, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2026 | — |
| S-1 | Registration statement | Apr 6, 2026 | — |
| S-8 | Employee stock plan registration | Mar 26, 2026 | — |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 16, 2026 | Mar 13, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 10, 2026 | Mar 4, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Feb 5, 2026 | Feb 4, 2026 |
| 8-K |
Current report
Material agreement
|
Nov 13, 2025 | Nov 10, 2025 |
| 8-K |
Current report
Other events
|
Nov 12, 2025 | Nov 12, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 12, 2025 | Sep 12, 2025 |
| 424B4 | Prospectus | Sep 12, 2025 | — |
| S-8 | Employee stock plan registration | Sep 11, 2025 | — |
| EFFECT | Filing | Sep 10, 2025 | — |
| S-1MEF | Filing | Sep 10, 2025 | — |
| CERT | Filing | Sep 10, 2025 | — |
| CORRESP | Letter to the SEC | Sep 9, 2025 | — |
| CORRESP | Letter to the SEC | Sep 9, 2025 | — |
| 8-A12B | Filing | Sep 9, 2025 | — |
| S-1/A | Amended registration statement | Sep 8, 2025 | — |
| CORRESP | Letter to the SEC | Sep 3, 2025 | — |
| CORRESP | Letter to the SEC | Aug 22, 2025 | — |
| S-1 | Registration statement | Aug 22, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2025 | — |
| DRSLTR | Filing | Jul 23, 2025 | — |
| DRS/A | Filing | Jul 23, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2024 | — |
| DRSLTR | Filing | Jun 24, 2024 | — |
| DRS/A | Filing | Jun 24, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 17, 2024 | — |
| DRS | Filing | May 20, 2024 | — |
| D/A | Filing | Jan 10, 2024 | — |
| D | Filing | Sep 21, 2023 | — |
| D/A | Filing | Nov 23, 2022 | — |
| D | Filing | Nov 1, 2022 | — |
| D | Filing | Jul 6, 2022 | — |
| D | Filing | Sep 1, 2020 | — |
| D | Filing | Dec 12, 2018 | — |
| D | Filing | Aug 27, 2018 | — |
| D | Filing | May 29, 2018 | — |
| D | Filing | Apr 6, 2017 | — |
| D | Filing | Dec 15, 2016 | — |
Showing 73 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1691082
- Former names
- LB PHARMACEUTICALS INC. (until Dec 12, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.